Two phase 3 trials of gantenerumab in early Alzheimer's disease
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer's disease. METHODS: We conducted two phase 3 trials (GRADUATE I and II) involving participants 50 to 90 years of age with mild cognitive impairment or mild dementia due to Alzheimer's disease and evidence of amyloid plaques on positron-emission tomography (PET) or cerebrospinal fluid (CSF) testing. Participants were randomly assigned to receive gantenerumab or placebo every 2 weeks. The primary outcome was the change from baseline in the score on the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB; range, 0 to 18, with higher scores indicating greater cognitive impairment) at week 116. RESULTS: A total of 985 and 980 participants were enrolled in the GRADUATE I and II trials, respectively. The baseline CDR-SB score was 3.7 in the GRADUATE I trial and 3.6 in the GRADUATE II trial. The change from baseline in the CDR-SB score at week 116 was 3.35 with gantenerumab and 3.65 with placebo in the GRADUATE I trial (difference, -0.31; 95% confidence interval [CI], -0.66 to 0.05; P = 0.10) and was 2.82 with gantenerumab and 3.01 with placebo in the GRADUATE II trial (difference, -0.19; 95% CI, -0.55 to 0.17; P = 0.30). At week 116, the difference in the amyloid level on PET between the gantenerumab group and the placebo group was -66.44 and -56.46 centiloids in the GRADUATE I and II trials, respectively, and amyloid-negative status was attained in 28.0% and 26.8% of the participants receiving gantenerumab in the two trials. Across both trials, participants receiving gantenerumab had lower CSF levels of phosphorylated tau 181 and higher levels of Aβ42 than those receiving placebo; the accumulation of aggregated tau on PET was similar in the two groups. Amyloid-related imaging abnormalities with edema (ARIA-E) occurred in 24.9% of the participants receiving gantenerumab, and symptomatic ARIA-E occurred in 5.0%. CONCLUSIONS: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline. (Funded by F. Hoffmann-La Roche; GRADUATE I and II ClinicalTrials.gov numbers, NCT03444870 and NCT03443973, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two phase III trials (NCT03444870 and NCT03443973) were recently terminated. In these trials, when assessing the efficacy and safety of gantenerumab (19) in participants with early (prodromal to mild) AD, the drug showed little clinical benefit in slowing cognitive decline, potentially due to limited clearance of amyloid plaques, with 5.0% participants experienced amyloid-related imaging abnormal”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [461]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Self-citation
Cited by
Items 201–300 of 312
CAPS: a simple clinical tool for β-amyloid positivity prediction in clinical Alzheimer syndrome
Lahiri, D., Lima, B. S., Roncero, C., Verhoeff, N. P. L. G., Freedman, M., Al‐Shamaa, S., & Chertkow, H. M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1422681 · Cited by 3
“While microhemorrhages do constitute an important substrate for cognitive decline and dementia (40, 41), for the purpose of anti-A β trials, people with more than 5 microbleeds are generally excluded at the point of screening (42).”
BackgroundAlam, J. J., & Sabbagh, M. N. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70035 · Cited by 2
Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time?
Schott, J. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00066-3 · Cited by 2
Health System Change for New Therapies in Alzheimer’s Disease: Putting the Cart Before the Horse?
Bocti, C. (2024) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2023.335 · Cited by 2
Immunotherapy of Alzheimer’s Disease
Tondo, G., Marchi, F. D., Anselmi, M., & Comi, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_51 · Cited by 1
Antibodies against Alzheimer's: Pioneering a New Era in Treatment Strategies
Verma, M., Singh, N. K., & Siddique, M. U. M. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072347198241226113039 · Cited by 1
Aortic Stiffness and Alzheimer’s Disease: The Medin Connection
Triposkiadis, F. K., Xanthopoulos, A. V., Boudoulas, H. K., & Brutsaert, D. L. (2025) · Biomolecules · doi:10.3390/biom15081148 · Cited by 2
Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease
Abdelmoity, O., Wisch, J. K., Kennedy, J. T., Goyal, M. S., Vlassenko, A. G., Flores, S. E., Handen, B. L., Head, E., Keator, D. B., Rafii, M. S., et al. (2025) · Annals of Neurology · doi:10.1002/ana.78002 · Cited by 3
Blood‐based pre‐screening in the SKYLINE secondary prevention Ph3 gantenerumab study
Bauer, A., Rabe, C., Schiffman, C., Rose, F., Respondek, G., Gullotta, F., Schlieker, L., Jethwa, A., Schrurs, I., Manuilova, E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70676 · Cited by 1
Self-citationSolving the 'Goldilocks problem' in dementia clinical trials with multimodal AI
Welchman, A. E., & Kourtzi, Z. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100397 · Cited by 3
“We analysed recruitment across major trials of AD therapeutics [12,14, 17 – 19, 32 Fig.”
Wang, B., Li, Y., Yao, T., Shen, X., Li, H., Jiang, W., Li, X., & Zhu, Z. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00963d · Cited by 3
Cao, Y., Willis, B. A., Horie, K., Wildsmith, K. R., Koyama, A., Sachdev, P., Penner, N., Charil, A., Irizarry, M. C., & Reyderman, L. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-026-00677-4 · Cited by 1
“Data were extracted from respective publications for TRAILBLAZER – ALZ 2 (donanemab) 27 , EMERGE (aducanumab) 28 , and GRADUATE I/II (gantenerumab) 29 .”
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
“The GRADUATE I NCT03444870and II NCT03443973trials tested high doses in early AD, achieving near-complete plaque clearance in many participants, but in 2022 reports from both trials showed no significant differences from placebo on primary cognitive endpoints (Bateman et al., 2023).”
Belavadi, S., & Kadiri, S. K. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178913 · Cited by 1
Friend or foe? Glial–vascular interactions in health and neurodegenerative disease
McQuaid, C., Sewell, M. D. E., & Montagne, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100143 · Cited by 1
Lovró, Z., Sandberg, A., Zetterberg, H., Pierrou, S. E., Parkkola, R., Sjögren, N., Scheinin, M., & Rinne, J. O. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02082-9 · Cited by 2
A protective role for APP in nuclear waste clearance via lysosomal exocytosis
Dougnon, G., Otsuka, T., Nakamura, Y., Sakai, A., Yamanaka, T., Matsui, N., Nakahara, A., Ito, A., Hatano, A., Matsumoto, M., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2524190123 · Cited by 4
Li, D., Zhang, Z., Lei, L. U., Liu, J., Cai, W., Hou, J., Lu, Y., & Yu, G. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112689 · Cited by 4
Vamanu, A., Maștaleru, A., Schreiner, T. G., Popescu, G., Roceanu, A. M., Cucu, A. I., Patrascu, A., Vulpoi, G.-A., Bilcu, R.-V., Cozma, S. R., et al. (2026) · Medical Sciences · doi:10.3390/medsci14030337 · Cited by 1
“Therefore, although the pooled effect observed in this meta-analysis reached statistical significance, the magnitude of benefit remains close to the lower boundary of what is generally considered clinically meaningful [30,31].”
InfluentialPieperhoff, L., Lorenzini, L., Almeida, F., Tranfa, M., Bollack, A., Arunachalam, P., Masserini, F., Wolz, R., Grootoonk, S., Ritchie, C. W., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71609 · Cited by 1
“44,45 The estimated years from biomarker positivity is calculated for each person by first solving this curve for time using a person’sobserved CL,andsubtractingtheestimatedA + durationfrom their age at that scan.”
Self-citationPredicting cognitive function in Alzheimer's clinical trials via amyloid β‐protein biomarkers
Sui, Z., Feng, A., Gong, Y., Zha, S., Lv, Y., Zheng, Q., Li, L., & Wang, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70665 · Cited by 1
Zhang, R. X., & Chen, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1856546 · Cited by 1
“This has reinforced a view of AD not as a disorder of amyloid alone but as the product of several interacting processes, including tau dysregulation, chronic neuroin fl ammation, cerebrovascular and blood-brain barrier (BBB) dysfunction, metabolic disturbance, and synaptic failure (12 – 18).”
Zhang, C., Zhang, J., Wang, Y., Wang, Y., Peng, L., Wang, Y., Tang, Z., Yu, J., Zhou, Q., & Cui, F. (2026) · Advanced Science · doi:10.1002/advs.76558 · Cited by 1
“While recent advances in anti-amyloid antibodies (e.g., Lecanemab) have shown efficacy in early-stage AD by clearing plaques [ 1, 43–45 ], they offer limited benefit for moderate-to-severe stages where neuronal loss is already extensive and irreversible [ 46–50 ].”
Sharma, A., Suresh, V., Kola, P. R., Raj, R. A., Javairia, F., Nithyanandam, A., Kaur, A., Arora, H., Uwishema, O., Gorty, D., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261466097 · Cited by 3
“21,24 Lecanemab.”
Anti-β amyloid immunotherapy: not clinically meaningful
Nonino, F., & Richard, E. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01432-7 · Cited by 1
Dementia, Driving, and the Duty to Warn
Redelmeier, D. A., & Bhatt, V. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.8856 · Cited by 1
Terapéutica con anticuerpos monoclonales en la enfermedad de Alzheimer
Maliza-Moposita, J. A., & Salazar-Garcés, L. F. (2024) · MQRInvestigar · doi:10.56048/mqr20225.8.3.2024.2739-2760
Boada, M., Neve, A., Das, B., Wojtowicz, J., Huang, Z., Bullain, S., Watkin, M., Lott, D., Bittner, T., Delmar, P., et al. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241303644 · Cited by 1
“As reported by others, 5,27 – 29 there was an association between APOE ϵ 4 carrier status and incidence of ARIA-E and ARIA-H seen in 50% of participants with the APOE 2 ϵ 4 genotype; a doubling of the incidence observed in participants with the APOE 1 ϵ 4 genotype.”
Self-citationPini, L., & Imbimbo, B. P. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70083 · Cited by 1
A Change of Mind: Targeting Amyloid-β with Better Safety Profile
Krick, K. E., & Wilcock, D. M. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-113434 · Cited by 1
Laurienti, P. J., Kritchevsky, S. B., Lyday, R. G., Tomlinson, C. E., Miller, M. E., Lockhart, S. N., Rundle, M. M., Hugenschmidt, C. E., Burdette, J. H., Shappell, H. M., et al. (2025) · Aperture Neuro · doi:10.52294/001c.141046 · Cited by 2
Li, Y., Schneider, L. S. S., & Wang, G. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70250 · Cited by 1
Yang, R., Li, Y., Zhao, X., Wang, L., Wu, J., & Sima, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.08.663694 · Cited by 3
“APOE isoforms are known to influence A β immunotherapy outcomes, including susceptibility to amyloid-related imaging abnormalities (ARIA) 33,34 .”
Strategies for Neuroprotection in Alzheimer's Disease
Jasutkar, H. G. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch5 · Cited by 1
Amyloid-Antikörper bei Alzheimer: kein signifikanter Einfluss auf klinische Progression
Krome, S. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2215-6389
Der monoklonale Antikörper Gantenerumab bei früher Alzheimer-Krankheit
Perneczky, R., (DNG), A. N. T. D. D. N. G., & Nitschmann, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01695-2
Paterno, G., Moore, B. D., Bell, B. M., Gorion, K.-M. M., Ran, Y., Prokop, S., Golde, T. E., & Giasson, B. I. (2024) · Antibodies · doi:10.3390/antib13030068
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical TrialsPreprint
Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, İ., Ghanbarian, E., Davatzikos, C. A., Lipton, R. B., Ezzati, A., & Initiative, A. D. N. (2024) · medRxiv · doi:10.1101/2024.09.03.24312481
Amyloid-Antikörper bei Alzheimer: kein signifikanter Einfluss auf klinische Progression
(2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2304-0804
Erichsen, P. A. (2024) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000077 · Cited by 1
Searching for new drugs to treat Alzheimer’s disease dementia through multiple pathways
Bai, H., & Feng, X.-F. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i1.100833
Laurienti, P. J., Kritchevsky, S. B., Lyday, R. G., Miller, M. E., Lockhart, S. N., Rundle, M. M., Hugenschmidt, C. E., Burdette, J. H., Shappell, H. M., Chen, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.07.622257
Immunotherapy for Alzheimer's disease: advances in adaptive immunity
Zhi, T. (2025) · New discovery. · doi:10.61958/ndfs3904
The Research Progress of Drugs for Treatment of Alzheimer’S Disease
Zhang, Y. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.20181
An, D., Li, X., & Xu, Y. Y. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111576 · Cited by 1
Bouvenot, G. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.02.009 · Cited by 2
Trends in Research on Gantenerumab for Alzheimer’s Disease: A Bibliometric and Thematic Analysis
Abdelwahab, S. İ., Taha, M. M. E., Alfaifi, H. A., Alzahrani, A. H., Aljahdali, I. A., Oraibi, O., Ali, S., Oraibi, B., Farasani, A. M., Jerah, A. A., et al. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273349645250324040257
The amyloid cascade hypothesis
Castellani, R. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-99651-8.00003-x
Biomarkers as Outcome Measures in Clinical Trials of Alzheimer Disease
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_15
Amyloid- and Tau-Targeted Therapies in Alzheimer’s Disease
Rajic, A. J., Galasko, D. R., & Tuszynski, M. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_17
Luque‐Tirado, A., García‐Roldán, E., González-Acosta, M., Herrera-Pozo, A., Mendoza, J. H., Almodóvar‐Sierra, Á., Marín-Cabañas, M., Sánchez‐Arjona, M. B., Vargas-Romero, J. P., & Macías, E. F. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251376906
“…measures have been predominantly used in two research contexts: observational cohort studies for the prediction of MCI and dementia 14 ; and clinical trials involving anti-amyloid therapy, 15,16 either during candidate screening, 15 or as an ef fi cacy measure within cognitive composite outcomes.”
Hypothesis-Driven Insights and Clinical Trial Updates in Alzheimer’s Disease Pathogenesis
Alhawarri, M. B. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273387383250924031644
Neuroinflammation and Autophagy in Neurodegenerative Therapy
Nadh, A. G., Chakraborty, S., Raju, R., Rizvi, A., & Chaudhary, R. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-3945-1_14 · Cited by 1
Protein Misfolding and Aggregation in the Pathogenesis of Alzheimer’s Disease
Kim, J., & Kim, H. (2025) · Gyemyeong uidae haksulji · doi:10.46308/kmj.2025.00164
Modeling amyloid plaque turnover dynamics improves characterization of drug effects
van Maanen, E., Robey, S., Bennacef, I., Duffull, S. B., Egan, M. F., Kennedy, M. E., & Stone, J. A. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70169
Teng, E., Li, Y., Blendstrup, M., & Lansdall, C. J. (2025) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000549652
Jin, K. L., Chezem, W. R., & Wang, G. (2025) · medRxiv · doi:10.64898/2025.12.10.25341978
Zhang, Y., Luo, X., Hong, H., Zhang, R., Wang, S., Liu, L., Lin, M., Li, K., Zeng, Q., Chen, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.71022
“34,35 To visualize model-derived trajectories, we stratified participants into prolonged and short lag subgroups using marker-specific median thresholds.”
Applying the Estimand Framework: Case Studies in Neuroscience
Burger, H. U., Sfikas, N., Magnusson, B., Josiassen, M. K., Quarg, P., Monnet, A., Anzures‐Cabrera, J., Shariati, N., & Delmar, P. (2025) · Springer series in pharmaceutical statistics · doi:10.1007/978-3-032-02192-2_9
Self-citationMapping the future of Alzheimer's disease research: Insights from global clinical trial data
Liu, X., Li, Y., Yu, Q., & Su, Y. (2026) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2026.100185
Cost‐effectiveness and impact at scale of collaborative care and lecanemab for Alzheimer's disease
Atkins, K. J., Kahn, J. G., & Possin, K. L. (2026) · Alzheimer s & Dementia Behavior & Socioeconomics of Aging · doi:10.1002/bsa3.70054 · Cited by 1
Schwab, D., Hofmann, C., Justies, N., Dickerson, D., Keshavarz, A., van Iersel, T. M., Martens, K., & Bittner, B. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70038
Konstantoulea, K., Ramakers, M., Borrie, S. C., T’Syen, D., Moechars, D., Śliwińska, M. A., Pradhan, B., Albertini, G., Baligács, N., Tsaka, G., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2516774123 · Cited by 1
“To determine whether therapeutic antibodies developed to target A β fibrils in the human brain could recognize THP - 1 - generated deposits, we tested four antibodies: Lecanemab, Aducanumab, Donanemab, and Gantenerumab ( 7, 9–11, 13, 37–39).”
Solis‐Urra, P., Olvera‐Rojas, M., García‐Rivero, Y., Zeng, X., Chen, Y., Sehrawat, A., Shekari, M., Oberlin, L. E., Erickson, K. I., Karikari, T. K., et al. (2026) · medRxiv · doi:10.64898/2026.03.02.26347392
Bousiges, O., Cretin, B., Battista, L., Schaeffer‐Agalède, C., Philippi, N., Hamied, L., Ravier, A., Demuynck, C., Muller, C., & Blanc, F. (2026) · GeroScience · doi:10.1007/s11357-026-02185-z · Cited by 1
Sharma, S., Sharma, U., Sethiya, N. K., & Singh, L. (2026) · Current Aging Science · doi:10.2174/0118746098373086251201095903 · Cited by 1
Duehring, J. A., Jacobs, D. M., Salmon, D. P., MacKelfresh, A., Revta, C., Meyer, A., Schaeffer, M., Schell-Mader, S., Wassmann, T., Wenzkowski, C., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100531
“Examples include the EMERGE and ENGAGE trials of aducanumab [3], the Clarity AD trial of lecanemab [1], the GRADUATE I and II trials of gantenerumab [11], the HOPE4MCI trial of the drug AGB101 [12], and the ongoing CELIA phase 2 trial to evaluate the safety and efficacy the drug BIIB080…”
Is Alzheimer’s an Autoimmune Disease?
Corrada, B. R., & Speth, R. C. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05790-3
Mapping individual molecular connectomes in Alzheimer's disease
Xu, Z., Mijalkov, M., Sun, J., Chang, Y., Sala, A., Volpe, G., Severino, M., Veronese, M., Ptacek, S. G., Pereira, J. B., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71310
“54,55 However, in our study we observed that these composite SUVR values cannot provide additional predictive power of longitudinal cognitive decline beyond the combination of age, sex, education, and dementia status in a consistent manner, performing well for a few cognitive domains but not for…”
Behl, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72210-7_18
Methodological innovations in drug development lifecycle with the advent of targeted immunotherapy
Abbas, R. (2024) · theses.fr (ABES) · doi:10.70675/62edf842z447dz4fcfz8051zd7ac23a193fa
Self-citationRole of T-cell immunity in the pathophysiology of Alzheimer’s disease and other Tauopathies
Matta, K. (2024) · theses.fr (ABES) · doi:10.70675/cea4fe5ez67c3z4445z92f7z39af62ba059b
Olson, C., Bravo, M. G., Gonzalez, G., & Camp, M. E. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250042
Patel, D., Patel, T., & Patel, P. N. (2026) · Cureus · doi:10.7759/cureus.107386 · Cited by 1
“For example, two phase 3 trials of gantenerumab in early Alzheimer’s did not demonstrate clinical benefit despite amyloid reduction, underscoring that amyloid clearance alone may be insufficient or that timing, dosing, and downstream biology matter [12].”
Jiang, Y., Ding, Y., Cao, Q., Wu, X., Li, X., Xu, Y., Zhao, Z., Xu, M., Lu, J., Wang, T., et al. (2026) · General Psychiatry · doi:10.1002/gps3.70013
Allouche, A., Colin, J., Birck, C., Schroeder, H., Tallandier, V., Baldoni, M., Muller, C., Afrassi, M., & Violle, N. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02051-2 · Cited by 1
“Among them, ALZ-801 [1], PH [36], Adu-canumab [1], Gantenerumab [2] and Lecanemab [3] have been tested in our primary cortical neuron cultures for their neuroprotective properties against AβO-induced toxicity (these experiments were carried out only once for indicative purposes).”
The clinical value of multimodal neuroimaging in monoclonal antibody therapy for Alzheimer's disease
Wang, Y., Li, H., Zhou, J., Zhao, S., Yang, A., & Li, Z. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1761380
“…of A β protofibrils (6), while long-term cerebral distribution studies of RmAb158 (the murine recombinant version of lecanemab) reveal effective blood-brain barrier penetration and sustained intracranial persistence, which may constitute a key mechanism underlying its therapeutic efficacy (20).”
Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials
Gobbi, S., Silvestri, E., Tonietto, M., Klein, G., van den Heuvel, M. P., & Magon, S. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70259
“The study designisexplained indetail in Batemanet al. 20”
Self-citationEx vivo comparison of ACU193 and lecanemab reveals binding differences in mouse brain
Grenon, M. B., Cline, E. N., Jerecìć, J., Johnson, E. A., Siemers, E., & Lemere, C. A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71509 · Cited by 1
Carrasco, M., Guzman, L., Barroso, E., Olloquequi, J., Cano, A., Ureña, J., Verdaguer, E., Prohens, R., Fortuna, A., Auladell, C., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02321-9
Concepts, types, and treatment strategies for neurodegenerative disorders
Rana, R., Jaiswal, S., Sethi, M., Tripathi, S., Mishra, K., Gupta, P., & Chourasia, M. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33623-2.00003-9
Fang, S., & Chen, S.-H. (2026) · Journal of Molecular Neuroscience · doi:10.1007/s12031-026-02560-7
Li, H., Liu, S., Luo, Z., & Wang, T. (2026) · Research Square · doi:10.21203/rs.3.rs-9932977/v1
Wu, Y., Di, Y., Wang, H. W., Wang, L., Zhang, J., Zhang, Y., & Lyu, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103216
Caselli, R. J., Geldmacher, D., & Schilling, T. (2026) · The Neurologist · doi:10.1097/nrl.0000000000000679
“29 The primary outcome measure was the change from baseline in CDR-GS score at week 116.”
InfluentialRennie, K., Tauskela, J. S., Ménard, M., Aylsworth, A., Comas, R., Whitfield, J., & Chakravarthy, B. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261453068
“…of BBB-ABP for oligomeric A β and the very low af fi nity of BBB-ABP for fi brillar forms of A β may reduce the likelihood of adverse effects associated with binding to fi brillar A β (as observed with monoclonal antibodies aducanumab, 35 lecanemab, 36 gantenerumab, 37,38 and donanemab 39,40 ).”
Modern pharmacotherapy of Alzheimer's disease: a review of approved and developed drugs
Gubernatorova, S. M., Levchina, A. K., & Vlasova, A. S. (2026) · Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery) · doi:10.33920/med-01-2606-17
The Promise and Peril of Alzheimer Disease Prevention
Grill, J. D., & Graff‐Radford, J. (2026) · Neurology · doi:10.1212/wnl.0000000000218348
Advancing Strain‐Specific Immunotherapy for Alzheimer's Disease and Tauopathies
Priya, E. S., Vasanth, S., Taj, T., Ameen, M. P. M., Danam, S. S., & Kumar, M. V. (2026) · Wiley eBooks · doi:10.1002/9781394336241.ch3
Sustaining Drug Discovery Amid the Limits of Alzheimer's Disease Immunotherapies
McDiarmid, A. (2026) · eNeuro · doi:10.1523/eneuro.0112-26.2026 · Cited by 1
Exploring Ion Channel‐Linked Strategies in Immunotherapy for Neurological Disorders
Hariprasad, M. G., GUHA, S., & Redhwan, M. A. M. (2026) · Wiley eBooks · doi:10.1002/9781394336241.ch11
Advances in modified anti-Aβ antibodies for the treatment of Alzheimer’s disease
Li, S., Gu, J., Xu, Z., He, C., & Yu, C. (2026) · BMC Medicine · doi:10.1186/s12916-026-05088-0
“However, pivotal Phase III clinical trial results demonstrated that these antibodies failed to significantly improve patients’ cognitive function, with some trials terminated due to insufficient efficacy or safety concerns [17–20].”
Pascual‐Lucas, M., Lacosta, A. M., Montañés, M., Canudas, J., Loscos, J., Monleón, I., Allué, J. A., Sarasa, L., Fandos, N., Romero, J., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71746
Self-citationVolume change with gantenerumab: Impact of amyloid‐related imaging abnormalities and amyloid removal
Tonietto, M., Silvestri, E., Belder, C. R. S., Barkhof, F., Fox, N. C., Smith, J., & Klein, G. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71749
“4 Although the gantenerumab program was terminated due to the benefit–risk observed in this population not supporting further development, a rich dataset was collected from nearly 2000 participants followed longitudinally for up to 116 weeks.”
Self-citationGantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta‐Analysis
Javed, M. N., Khan, S. M., Mustafa, S., Mujtaba, A., Amin, H., Azhar, N. A., Hameed, A., Zayed, A., Khalid, M., & Hussain, J. M. (2026) · Brain and Behavior · doi:10.1002/brb3.71643
“While headache was reported frequently, its primary cause in these patients is localized neuro-inflammation triggered by the antibody’s mechanism of action (Bateman et al. 2023 ; Salloway et al. 2024 ).”
The Dementia Trials Accelerator (DTA): a UK dementia trials-ready cohortPreprint
Whiteley, W. N., van Duijn, C. M., Postlethwaite, N., Beal, E., Bennett, K., Blakoe, G., Brooks, H., Collet, K., Elliott, P., Forde, E., et al. (2026) · medRxiv · doi:10.64898/2026.08.14.26359869
Emanuele, E., & Minoretti, P. (2026) · The FASEB Journal · doi:10.1096/fj.202601680rr
“Similarly, gan-tenerumab—despite achieving robust amyloid plaque clearance in Phase 3 trials—produced only mixed evidence for slowing cognitive decline in patients with dominantly inherited AD [21, 22].”
Hendrix, S. B., Mallinckrodt, C. H., Abschneider, R. M., Atri, A., Bendtsen, M. D., León, T., Feldman, H., Johannsen, P., & Cummings, J. L. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71676 · Cited by 1
“20 21 Fortheprimaryesti-mand in GRADUATE I and II, a treatment policy approach was used for all SDCR ICEs, whereas all NSDCR ICEs were handled using a hypothetical approach, with missing data imputed with the standard missing-at-random assumption.”
Self-citationNovel therapies in Alzheimer’s disease
Pavăl, D., Căpățînă, O., & Stănculete, M. F. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.026
Song, B., Wang, W., Liu, S., Jin, X., Yan, Q., Li, M., Yue, D., Liu, Y., Li, X., Yin, L., et al. (2026) · Aging Cell · doi:10.1111/acel.70699
“Results from Phase III clinical trials indicate that Gantenerumab does not show significant improvement in the primary outcome measure (Clinical Dementia Rating Scale-Sum of Boxes score), and patients carrying the APOE ε4 allele have a higher incidence of cerebral edema (Bateman et al. 2023).”
Metadata
- Authors
- Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., Wojtowicz, J., Blennow, K., Bittner, T., Black, S. E., Klein, G., Boada, M., Grimmer, T., Tamaoka, A., Perry, R. J., Turner, R. S., Watson, D., Woodward, M., Thanasopoulou, A., Lane, C., Baudler, M., Fox, N. C., Cummings, J. L., Fontoura, P., & Doody, R. S.
- Affiliations
- Washington University in St. Louis (US)
- Roche (United Kingdom) (GB)
- University of Southern California (US)
- F. Hoffmann-La Roche AG (CH)
- Brown University (US)
- Sahlgrenska University Hospital (SE)
- University of Toronto (CA)
- From the Department of Neurology, Washington University School of Medicine, St. Louis (R.J.B.); Roche Products, Welwyn Garden City (J.S., C.L.), and the Department of Brain Sciences, Faculty of Medicine, Imperial College London (R.J.P.), and the Dementia Research Centre, Department of Neurodegenerative Disease, and the U.K. Dementia Research Institute, Queen Square Institute of Neurology, University College London (N.C.F.), London — all in the United Kingdom; the Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego (M.C.D.), and Genentech, South San Francisco (T.B., R.S.D.) — both in California; F. Hoffmann–La Roche, Basel, Switzerland (P.D., R.A., J.W., T.B., G.K., A. Thanasopoulou, M. Baudler, P.F., R.S.D.); Butler Hospital and Warren Alpert Medical School, Brown University, Providence, RI (S.S.); the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, and the Clinical Neurochemistry Laboratory, Sahlgrens...
- TUM Klinikum (DE)
- University of Tsukuba (JP)
- UCL Queen Square Institute of Neurology (GB)
- Georgetown University (US)
- Austin Hospital (AU)
- UK Dementia Research Institute (GB)
- University of Nevada, Las Vegas (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-11-16
- Volume
- 389
- Issue
- 20
- Pages
- 1862-1876
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10794000
- OpenAlex
- W4388688059
- Cited by
- 314
- References
- 30
- Citations by year
- 2026: 91 · 2025: 120 · 2024: 100 · 2023: 3
- FWCI
- 55.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- HAL (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- gantenerumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, mild cognitive impairment, mild dementia, amyloid PET, cerebrospinal fluid biomarkers, cognitive decline, treatment discontinuation, safety and tolerability, subcutaneous administration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Antibodies, Monoclonal, Humans, Middle Aged, Amyloid beta-Peptides, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.